-
1
-
2
-
3
-
4
Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis 1 1 Work was performed at Stanford University School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine; the Graduate School of Business of Stanford University; and Sunnybrook and Women's College Health Sciences Centre, University of Toronto. Subsequent to completion of this economic evaluation, Robert Fowler, has
Veröffentlicht in Journal of critical care
VolltextArtikel -
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20